However, ezetimibe did not inhibit vascular lipid accumulation or macrophage recruitment induced by HCD when apolipoprotein A-II was knocked out, implying that apolipoprotein A-II plays a pivotal role in reducing AS caused by HCD (Yan et al., 2019). This evidence concerns the gene APOA2 and heavy chain disease.